MFDA Issues Caution over Immunoglobulin Batches

The Maldives Food and Drug Authority (MFDA) has issued a public advisory regarding quality concerns identified in several batches of Normal Immunoglobulin for Intravenous Use BP 5% (brand name: Immuglo), manufactured by India’s Ichor Biologics Limited.

According to the MFDA’s announcement yesterday, Sri Lanka’s National Medicines Regulatory Authority, in collaboration with the World Health Organization (WHO), had flagged potential issues with the following batches of the product: IG24001AD, IG24002AD, IG24003AD, and IG24004AD.

advertisement

advertisement

advertisement

The MFDA noted that Ichor Biologics Limited is not on the approved list of suppliers authorised to import or distribute medicines within the Maldives. No records indicate that these batches have been brought into the country.

pic.twitter.com/VLMLAbEy9M— MFDA (@MFDA_mv) October 27, 2024

However, the advisory was issued as a precautionary measure. The MFDA highlighted that many Maldivians travel to India and Sri Lanka for medical treatment and may source medications from these countries for personal use.

Human normal immunoglobulin is a medication used to boost the immune system by providing essential antibodies to fight infections.

The MFDA has advised members of the public seeking further information on this advisory to contact their hotline at 7200321.